Organoidsciences Ltd. (KOSDAQ:476040)

Market Cap	207.46B
Revenue (ttm)	2.52B
Net Income (ttm)	-13.28B
Shares Out	6.55M
EPS (ttm)	-2,430.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	242,174
Average Volume	643,664
Open	33,300
Previous Close	33,300
Day's Range	31,800 - 33,500
52-Week Range	23,000 - 52,000
Beta	n/a
RSI	36.87
Earnings Date	Nov 14, 2025

About Organoidsciences

Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Employees: 76
• Stock Exchange: KOSDAQ
• Ticker Symbol: 476040

Financial Performance

In 2024, Organoidsciences's revenue was 1.95 billion, an increase of 22.77% compared to the previous year's 1.59 billion. Losses were -11.25 billion, -70.93% less than in 2023.